ニュース

最新ニュース

Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy

Newton Biocapital 3rd Annual Recital & Networking Cocktail Flagey

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Nikkei Bio Article: AMED's Drug Discovery Venture Ecosystem Enhancement Project Selected for the First Time by Two Companies - Edit Force and Immunohelix

EditForce, Inc. announced that our "Development of an Innovative Treatment for Myotonic Dystrophy Type 1 by a Sequence--Specific RNA Binding Protein Targeting Pathogenic CUG Repeat

EditForce, Inc. (Headquarter: Fukuoka, President and CEO: Takashi Ono) announces that we have raised a total of 1.8 billion yen through a third-party allotment of new shares by March 22, 2023.

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure

Certified VC interview Newton Biocapital Partners Sadashi Suzuki by Medical Innovation Support Office (MEDISO) - Japanese Ministry of Health and Labour

4
5
6
7
8